A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

United States

Moffitt Cancer Center, Tampa, Florida

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Icahn School of Medicine at Mount Sinai, New York, New York

Weill Cornell Medical Center, New York, New York